Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b pivotal study of izokibep in moderate to severe hidradenitis suppurativa
2021-005713-13Phase 2Completed
- Sponsor
- Acelyrin
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of izokibep in hidradenitis suppurativa (HS), sponsored by Acelyrin. Started Apr 2022; status: completed.
02
Drugs
izokibep
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2021-005713-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005713-13.